1. Report Introduction 2. Cystic fibrosis 2.1. Overview 2.2. History 2.3. Cystic fibrosis Symptoms 2.4. Causes 2.5.Pathophysiology 2.6. Cystic fibrosis Diagnosis 2.6.1. Diagnostic Guidelines 3. Cystic fibrosis Current Treatment Patterns 3.1. Cystic fibrosis Treatment Guidelines 4. Cystic fibrosis - DelveInsight's Analytical Perspective 4.1. In-depth Commercial Assessment 4.1.1. Cystic fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends 4.1.1.1. Assessment Summary 4.1.2. Cystic fibrosis Collaboration Deals 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis 4.1.2.3. Cystic fibrosis Acquisition Analysis 5. Therapeutic Assessment 5.1. Clinical Assessment of Pipeline Drugs 5.1.1. Assessment by Phase of Development 5.1.2. Assessment by Product Type (Mono / Combination) 5.1.2.1. Assessment by Stage and Product Type 5.1.3. Assessment by Route of Administration 5.1.3.1. Assessment by Stage and Route of Administration 5.1.4. Assessment by Molecule Type 5.1.4.1. Assessment by Stage and Molecule Type 5.1.5. Assessment by MOA 5.1.5.1. Assessment by Stage and MOA 5.1.6. Assessment by Target 5.1.6.1. Assessment by Stage and Target 6. Cystic fibrosis Late Stage Products (Phase-III) 7. Cystic fibrosis Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Cystic fibrosis Discontinued Products 13. Cystic fibrosis Product Profiles 13.1. Drug Name: Company 13.1.1. Product Description 13.1.1.1. Product Overview 13.1.1.2. Mechanism of action 13.1.2. Research and Development 13.1.2.1. Clinical Studies 13.1.3. Product Development Activities 13.1.3.1. Collaboration 13.1.3.2. Agreements 13.1.3.3. Acquisition 13.1.3.4. Patent Detail 13.1.4. Tabulated Product Summary 13.1.4.1. General Description Table Detailed information in the report? 14. Cystic fibrosis Key Companies 15. Cystic fibrosis Key Products 16. Dormant and Discontinued Products 16.1. Dormant Products 16.1.1. Reasons for being dormant 16.2. Discontinued Products 16.2.1. Reasons for the discontinuation 17. Cystic fibrosis Unmet Needs 18. Cystic fibrosis Future Perspectives 19. Cystic fibrosis Analyst Review 20. Appendix 21. Report Methodology 21.1. Secondary Research 21.2. Expert Panel Validation

Table 1: Cystic fibrosis Diagnostic Guidelines Table 2: Cystic fibrosis Treatment Guidelines Table 3: Assessment Summary Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis Table 5: Cystic fibrosis Acquisition Analysis Table 6: Assessment by Phase of Development Table 7: Assessment by Product Type (Mono / Combination) Table 8: Assessment by Stage and Product Type Table 9: Assessment by Route of Administration Table 10: Assessment by Stage and Route of Administration Table 11: Assessment by Molecule Type Table 12: Assessment by Stage and Molecule Type Table 13: Assessment by MOA Table 14: Assessment by Stage and MOA Table 15: Assessment by Target Table 16: Assessment by Stage and Target Table 17: Cystic fibrosis Late Stage Products (Phase-III) Table 18: Cystic fibrosis Mid Stage Products (Phase-II) Table 19: Cystic fibrosis Early Stage Products (Phase-I) Table 20: Pre-clinical and Discovery Stage Products Table 21: Inactive Products Table 22: Dormant Products Table 23: Discontinued Products Figure 1: Disease Overview Figure 2: History Figure 3: Symptoms Figure 4: Causes Figure 5: Pathophysiology Figure 6: Diagnostic Guidelines Figure 7: Treatment Guidelines Figure 8: Cystic fibrosis companies collaborations, Licensing, Acquisition -Deal Value Trends Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis Figure 10: Cystic fibrosis Acquisition Analysis Figure 11: Assessment by Phase of Development Figure 12: Assessment by Product Type (Mono / Combination) Figure 13: Assessment by Stage and Product Type Figure 14: Assessment by Route of Administration Figure 15: Assessment by Stage and Route of Administration Figure 16: Assessment by Molecule Type Figure 17: Assessment by Stage and Molecule Type Figure 18: Assessment by MOA Figure 19: Assessment by Stage and MOA Figure 20: Late Stage Products (Phase-III) Figure 21: Mid Stage Products (Phase-II) Figure 22: Early Stage Products (Phase-I) Figure 23: Pre-clinical and Discovery Stage Products Figure 24: Inactive Products Figure 25: Dormant Products Figure 26: Discontinued Products Figure 27: Unmet Needs